Zimmer Biomet

ZBH

Market cap $19.7B

Zimmer Biomet Holdings is rated a BUY, driven by innovation momentum and undervalued valuation despite recent stock underperformance. ZBH's 'Magnificent 7' products, strategic acquisitions like Monogram Technologies, and strong cash flow underpin a compelling medium- to long-term investment thesis. Key risks include acquisition integration, margin pressure, regulatory challenges, and operational disruptions from a failed ERP rollout and ongoing litigation.

Zimmer Biomet expands its foot & ankle trauma lineup with Gorilla Pilon Fusion & Phantom TTC Trauma Nail launches.

Gorilla® Pilon Fusion Plating System Introduced for Complex Ankle Fusions Phantom® TTC Trauma Nail Enhances Treatment Options for Complex Hindfoot Injuries WARSAW, Ind., Oct. 8, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, and Paragon 28, a wholly owned subsidiary, today announced the full commercial launch of two innovative solutions for complex foot and ankle trauma to offer surgeons advanced tools to address challenging pilon fractures and hindfoot injuries with precision and efficiency.

Transaction creates the  broadest, most flexible portfolio of orthopedic robotics and navigation technologies, including pathway towards the first fully autonomous robotic technology for orthopedic procedures  WARSAW, Ind., Oct. 7, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) ("Zimmer Biomet"), a global medical technology leader, today announced it has completed the acquisition of Monogram Technologies Inc. ("Monogram"), an AI-driven, next-generation orthopedic robotics company.

ASHBURN, Va.--(BUSINESS WIRE)--I2Pure, a leader in molecular iodine technology, today celebrates Zimmer Biomet's recent achievement in receiving Japan's Pharmaceutical and Medical Devices Agency (PMDA) approval for orthopedic implants utilizing iodine technology to inhibit bacterial adhesion on implant surfaces. This milestone represents further validation of molecular iodine's therapeutic potential in advanced medical applications. “We could not be more pleased to see Zimmer Biomet and the Jap.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

WARSAW, Ind. , Oct. 3, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced its third quarter earnings conference call will be webcast on Wednesday, November 5, 2025 at 8:30 a.m.

Zimmer Biomet wins early PMDA approval in Japan for its iTaperloc Complete and iG7 Hip System with Iodine Technology.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Investors with an interest in Medical - Products stocks have likely encountered both Zimmer Biomet (ZBH) and EssilorLuxottica Unsponsored ADR (ESLOY). But which of these two companies is the best option for those looking for undervalued stocks?